Impact of Transfusion on Cancer Growth and Outcome
| Autor: | Jerard Seghatchian, Mohamed Elemary, Hadi Goubran, Thierry Burnouf, Magdy El-Ekiaby, Miryana Radosevich |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
tumor Evidence-based practice Pharmacy Disease Review 030204 cardiovascular system & hematology lcsh:RC254-282 Metastasis Blood cell 03 medical and health sciences 0302 clinical medicine medicine cancer metastasis Clinical significance Intensive care medicine plasma transfusion platelet microparticles biological response modifiers business.industry Cancer General Medicine lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease medicine.anatomical_structure 030220 oncology & carcinogenesis Personalized medicine business Biomedical engineering red blood cells |
| Zdroj: | Cancer Growth and Metastasis Cancer Growth and Metastasis, Vol 2016, Iss 9, Pp 1-8 (2016) Cancer Growth and Metastasis, Vol 9 (2016) |
| ISSN: | 1179-0644 |
| Popis: | For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|